Pharmaceutical Contract Manufacturing - Global Strategic Business Report

Description: The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables, Solid Dosage Forms, and Liquid & Semi-solid Dosage Forms.

Company profiles are primarily based on public domain information including company URLs. The report profiles 112 companies including many key and niche players such as -

Aenova Group
Ajinomoto Althea, Inc.
Albany Molecular Research Inc.
Alcami Corporation
Baxter International, Inc.

Contents:
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
Pharmaceutical Contract Manufacturing
A Prelude
Current & Future Market Outlook
Sizing the Market
West Leads in PCM Services
Solid Dosage Remains Popular Among CMOs
Injectable-Dose Formulations to Spearhead Growth of the PCM Market
Opportunities Rife for PCM Growth
Key Market Drivers
Major Changes Imperative to Capitalize on Brighter Future Prospects

2. MARKET TRENDS & DRIVERS
Changing Face of the CMO Industry
Relevance of CMOs Increases in the Modern Pharma Industry
Patent Expiries Augur Good Tidings for the PCM Market
PCMs Gear Up to Tap Booming Biologics Market
Biotechnology Start-Ups Spur Demand for Contract Manufacturing
Service Differentiation
The Key to Future Success in Solid Dosage Formulations Manufacturing
Strong Growth in Injectables Market to Resonate in Contract Manufacturing
Developed Markets Dominate Sterile Injectables Contract Manufacturing Market
PCM Market for Vaccines Yet to Take Off
PCM Industry Gravitates Eastward, and Subsequently Leads to Near-Shoring
Smaller Production Batches are Here to Stay; Compel Facility Efficiency Improvements
Upstream Movement Becomes a Compulsion for Many
Need to Focus on Better Customer Services Emerges
Rising Drug Complexity Presses for Specialized Expertise
Adoption of Cutting-Edge Technologies to Radicalize PCM Environment
RABS technology
Quality by Design
Track & Trace Techniques
Disposable Processing Techniques
Upstream & Downstream Processes
Process Analytical Technology
Near Infrared Spectroscopy
Perfusion Technology Takes Center-stage as Quality and Cost Concerns Rise
Downstream Processes Get a Lift as CMOs Seek Ways to Improve Capacity
Biopharma Contract Manufacturing Surges Ahead
Cost and Risk Containment Objectives Spur Outsourcing of Biopharma Production
Contract Manufacturing of ADCs Continues to Rise
Competition to Surge in Biological Contract Manufacturing Market
CMOs Gear Up for Capacity Expansions to Address Growing Demand from Biopharma
Ballooning Global Population Offers Increased Growth Opportunities

Table 1: Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (includes corresponding Graph/Chart)
Aging Population Boosts Opportunities for PCM
Table 2: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart)
Table 3: Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart)
Table 4: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
Increasing Healthcare Expenditure to Spur Demand for Contract Manufacturing of Generics
Table 5: Healthcare Spending as a Percentage of GDP by Region (2016E) (includes corresponding Graph/Chart)
Table 6: Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2014) (includes corresponding Graph/Chart)
Surge in Generic Drugs to Benefit Pharmaceutical Contract Manufacturers
Table 7: Worldwide Annual Spending on Drugs by Category (2011 & 2015): Percentage Breakdown of Dollar Sales for Branded Drugs, Generic Drugs, and Others (includes corresponding Graph/Chart)
Insourcing of Manufacturing Operations
An Emerging Threat to PCM
Vendor Switching- A Growing Concern for PCMs
New Challenges Threaten Prospects for CMOs
New Distribution Regulations Incites Changes in Operations

3. COMPETITIVE LANDSCAPE
PCM
A Highly Fragmented Industry Undergoing Consolidation
Table 8: Leading Players in the Global Finished Dose Pharmaceutical Contract Manufacturing Market (2015): Percentage Breakdown of Revenues for Aenova, Baxter, Catalent, Famar, Fareva, LTS Lohmann, Nipro, Patheon/Dpx, Pfizer/Hospira, Vetter and Others (includes corresponding Graph/Chart)
Table 9: Worldwide Injectables Contract Manufacturing Market by Leading Players (2013): Percentage Breakdown of Value Sales for Baxter, Hospira, Vetter and Others (includes corresponding Graph/Chart)
PCMs Battle Fierce Competition and Commoditization
Consolidation Wave Hits the Market
Select Key CMO Mergers and Acquisitions: 2014-2016
Changing Focus on M&A Activity
Investments Rise as CMOs Respond to Changing Market Needs
Capacity Expansions Become Popular Options for Building Integrated Service Offerings
Competition Heats Up in Injectables Market, PCMs Expand Capabilities and Service Offerings
Increased Regulator Scrutiny: A Cause of Concern for the Emerging Market PCMs

4. SERVICE OVERVIEW
Introduction
Injectables (Injections, Vials, and IV solutions)
Solid Dosage Forms (SDFs) (Tablets and Capsules)
Liquid Dosage Forms (LDFs) (Syrups and Suspensions)
An Insight into the Rise of Pharmaceutical Contract Manufacturing
Investment Risks in Pharmaceutical Contract Manufacturing
Quality Assurance Risk
Drug Development Risk
Acquisition Risk
Client Dependency Risk

5. RECENT INDUSTRY ACTIVITY
KDPharma to Merge with Marine Ingredients
Suanfarma Acquires Stake in Idifarma
Recipharm Inks Long-Term Commercial Manufacturing Contract with Tillots
Propanc Inks Contract Manufacturing Deal with AmatsQBiologicals
BioTechnique Commences Vaccine Manufacturing under Partnership with NPO
Piramal Pharma Solutions Acquires Ash Stevens
Saneca Sells Registration Dossiers for 20 Products to Xantis, Retains Manufacturing Rights
Evonik Takes Over Transferra
Famar to Acquire Roche's Leganes Site
Mylan Acquires Part Business of Renaissance
Averica and Dalton Pharma Ink Preferred Provider Agreement
AGC Asahi Glass Takes Over Biomeva
BioDuro and Formex Merge
Frontida Acquires Sun Pharma's US Manufacturing Facilities
Recipharm Inks Agreement to Take Over CDMO from Kemwell
Generic Specialties Takes Over Axxcelerate Pharma
Pfizer Establishes Pfizer CentreOne Specialty CMO
Caisson Biotech Inks Manufacturing Agreement with CordenPharma
Brammer and Florida Biologix Merge
AlPharma and Cambridge Major Laboratories Merge to form Alcam
Recipharm to Acquire Mitim
TxCell Signs CMO Deal with MaSTherCell
Boehringer Ingelheim to Commence First Biopharma CMO Pilot Project in China
Enteris Commences Contract Manufacturing Service at its Facility
Capsugel Takes Over Powdersize and Xcelience
Synerlab Acquires Alcama Farma
Recipharm Inks Deal to Take Over Majority Stake in Nitin Lifesciences
Pfizer Acquires Hospira
Avista Pharma Takes Over Scynexis CMO and Animal Health Businesses
Lonza and Nikon Team Up for New Contract Manufacturing Facility
Piramal Acquires Coldstream
SK Capital Takes Over Halo Pharmaceutical
FUJIFILM Acquires Kalon Biotherapeutics
Bayer Selects Cardinal Health as Contract Manufacturer for Xofigo®
Recipharm Takes Over Manufacturing Facility and Contracts from Flamel
Baring to Acquire Bushu Pharmaceuticals
Recipharm Takes Over Lusomedicameta
Strides Arcolab and Shasun to Merge
Kinex Pharmaceuticals Acquires QuaDPharma
Patheon Acquires Gallus BioPharmaceuticals
Packaging Coordinators Takes Over Penn Pharma
Sun Pharmaceutical Takes Over Pharmalucence
AMRI Acquires Oso Biopharmaceuticals Manufacturing
Carlyle Group Takes Over Sunsho Pharmaceutical
AMRI Acquires Cedarburg
Par Pharmaceutical to Take Over JHP
JLL Partners and Royal DSM Merger Businesses to form DPx
Meiji Holdings Buys Medrech Lifecare Limited
Emilia Group Takes Over Pharma Pac LLC
Emergent BioSolutions Takes Over Cangene Corporation

6. FOCUS ON SELECT PLAYERS
Aenova Group (Germany)
Ajinomoto Althea, Inc. (US)
Albany Molecular Research Inc. (US)
Alcami Corporation (US)
Baxter International, Inc. (US)
Boehringer Ingelheim GmbH (Germany)
Catalent Pharma Solutions, Inc. (US)
Cobra Biologics Holding AB (Sweden)
CordenPharma International (Germany)
Dishman Group (India)
DPX Holdings B.V. (US)
Fareva Group (Luxembourg)
Famar Health Care Services (Greece)
Hospira, Inc. (US)
Jubilant Life Sciences Limited (India)
Kemwell Biopharma Pvt. Ltd. (India)
Lanza Group Ltd. (Switzerland)
LTS Lohmann Therapie-Systeme AG (Germany)
NextPharma Technologies Holding Ltd. (UK)
Nipro Pharma Corporation (Japan)
Recipharm AB (Sweden)
Vetter Pharma International GmbH (Germany)

7. GLOBAL MARKET PERSPECTIVE
Table 10: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 11: World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 12: World 14-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region
Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
Table 13: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 14: World Historic Review for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 15: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region
Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
Table 16: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 17: World Historic Review for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 18: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region
Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
Table 19: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 20: World Historic Review for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 21: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region
Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
III. MARKET

1. THE UNITED STATES
A. Market Analysis
   US PCM Market Overview
   Domestic Contract Manufacturing Market Sees New Vigor
   Competitive Landscape
   Strategic Corporate Developments
   Select Key Players
B. Market Analytics
   Table 22: The US Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
   Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
   Table 23: The US Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
   Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
   Table 24: The US 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
   Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

2. CANADA
A. Market Analysis
   Current & Future Analysis
   Strategic Corporate Developments
B. Market Analytics
   Table 25: Canadian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
   Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
   Table 26: Canadian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
   Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
   Table 27: Canadian 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
   Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

3. JAPAN
A. Market Analysis
   Current & Future Analysis
   Strategic Corporate Developments
   Nipro Pharma Corporation
   A Key Japanese Player
B. Market Analytics
   Table 28: Japanese Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
   Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
   Table 29: Japanese Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).

Table 30: Japanese 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).

4. EUROPE
A. Market Analysis
  Market Overview
  Injectables Segment Offers Promising Potential
  Mammalian Cell Technology Dominates PCM Market
  Competitive Scenario
  Overview of Select Markets
  Germany
  Russia
B. Market Analytics
  Table 31: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region
  France, Germany, Italy, UK, Spain and Rest of European Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).
  Table 32: European Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region
  France, Germany, Italy, UK, Spain and Rest of European Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).
  Table 33: European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region
  Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK, Spain and Rest of European Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).
  Table 34: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
  Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).
  Table 35: European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
  Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).
  Table 36: European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
  Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).

4a. FRANCE
A. Market Analysis
  Current & Future Analysis
  Strategic Corporate Development
B. Market Analytics
  Table 37: French Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
  Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).
  Table 38: French Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
  Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).
  Table 39: French 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
  Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels,
Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4b. GERMANY
A. Market Analysis
Current & Future Analysis
Strategic Corporate Developments
Key Players
B. Market Analytics
Table 40: German Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 41: German Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 42: German 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4c. ITALY
A. Market Analysis
Current & Future Analysis
Strategic Corporate Development
B. Market Analytics
Table 43: Italian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 44: Italian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 45: Italian 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM
A. Market Analysis
Current & Future Analysis
Strategic Corporate Development
Key Player
B. Market Analytics
Table 46: UK Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 47: UK Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 48: UK 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
4e. SPAIN
A. Market Analysis
   Current & Future Analysis
   Strategic Corporate Developments
B. Market Analytics
   Table 49: Spanish Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
   Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
   Table 50: Spanish Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
   Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
   Table 51: Spanish 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
   Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
4f. REST OF EUROPE
A. Market Analysis
   Current & Future Analysis
   Strategic Corporate Developments
   Key Players
B. Market Analytics
   Table 52: Rest of European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
   Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
   Table 53: Rest of European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
   Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
   Table 54: Rest of European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
   Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
5. ASIA-PACIFIC
A. Market Analysis
   Favorable Government Policies Transform China and India into PCM Hubs
   Competitive Scenario
   Overview of Select Key Markets
   India
   India
A Stronghold for Pharmaceutical Contract Manufacturing
   Market Sees Transitory Turbulence
   Indian PCMs Battle Soaring Costs
   Outlook Remains Promising
   China
   China Presents Enormous Opportunities for Contract Manufacturing
   Strategic Corporate Developments
   Select Key Players
B. Market Analytics
   Table 55: Asia-Pacific Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form
   Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding...
Table 56: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid &
Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with
Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding
Graph/Chart)

Table 57: Asia-Pacific 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid
Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels,
Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

6. REST OF WORLD
Market Analysis
Table 58: Rest of World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing
by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid &
Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with
Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding
Graph/Chart)

Table 59: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form
Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid &
Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with
Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding
Graph/Chart)

Table 60: Rest of World 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form
Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid
Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels,
Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 112 (including Divisions/Subsidiaries 125)
The United States (54)
Canada (2)
Japan (7)

- Europe (40)
- France (6)
- Germany (10)
- The United Kingdom (7)
- Italy (3)
- Spain (2)
- Rest of Europe (12)

Asia-Pacific (Excluding Japan) (21)
Middle East (1)

Ordering: 
Order Online - http://www.researchandmarkets.com/reports/347965/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Pharmaceutical Contract Manufacturing - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/347965/
Office Code: SC2GUTI5

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 4950</td>
</tr>
<tr>
<td>1 - 5 Users:</td>
<td>USD 6930</td>
</tr>
<tr>
<td>1 - 10 Users:</td>
<td>USD 9405</td>
</tr>
<tr>
<td>1 - 15 Users:</td>
<td>USD 11880</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World